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ORIGINAL RESEARCH
Anticoagulant Therapy in Initially Low-Risk 
Patients With Nonvalvular Atrial Fibrillation 
Who Develop Risk Factors
Sun Young Choi, PhD; Moo Hyun Kim , MD; Kwang Min Lee, PhD; Young-Rak Cho, MD;  
Jong Sung Park, MD; Seong Woo Kim, MD; Jin Kyung Kim, MD; Matthew Chung, MD; Sung-Cheol Yun, PhD; 
Gregory Y. H. Lip , MD
BACKGROUND: The CHA2DS2-VASc score has been validated for stroke risk prediction in patients with atrial fibrillation (AF). 
Antithrombotic therapy is not recommended for low-risk patients with AF (CHA2DS2-VASc 0 [male] or 1 [female]). We studied 
a cohort of initially low-risk patients with AF in relation to their development of incident comorbidities and their treatment on 
oral anticoagulation therapy.
METHODS AND RESULTS: We assessed data from 14 441 low-risk patients with AF (CHA2DS2-VASc score of 0 [male] or 1 
[female]) using the Korean National Health Insurance Service database, in relation to their development of incident stroke 
risk factors and adverse outcomes. The clinical end point was the occurrence of ischemic stroke, major bleeding, all-cause 
death, or the composite outcome (ischemic stroke + major bleeding + all-cause death). In our cohort, 2615 (29.1%) male 
and 1650 (30.3%) female patients acquired at least 1 new stroke risk factor during a mean follow-up of 2.0 years. Among 
the patients with an increasing CHA2DS2-VASc score ≥1, male and female patients treated with oral anticoagulants had a 
significantly lower risk of ischemic stroke (male: hazard ratio [HR], 0.62 [95% CI, 0.44–0.82; P=0.003]; female: HR, 0.65 
[95% CI, 0.47–0.84; P=0.007]), all-cause death (male: HR, 0.67 [95% CI, 0.49–0.88; P=0.009]; female: HR, 0.82 [95% CI, 
0.63–1.02; P=0.185]), and composite outcomes (male: HR, 0.78 [95% CI, 0.61–0.95; P=0.042]; female: HR, 0.79 [95% CI, 
0.62–0.96; P=0.045]) than patients not treated with oral anticoagulants.
CONCLUSIONS: Approximately 30% of patients acquired ≥1 stroke risk factor over a 2-year follow-up period. Low-risk patients 
with AF should be regularly reassessed to adequately identify those with incident stroke risk factors that would merit throm-
boprophylaxis for the prevention of stroke and the composite outcome.
Key Words: anticoagulant ■ atrial fibrillation ■ death ■ intracranial hemorrhage ■ stroke
Atrial fibrillation (AF) is a major cause of isch-emic stroke, and AF-related stroke has a worse prognosis and a higher recurrence rate than 
non–AF-related stroke.1 Most international guidelines 
recommend the use of the CHA2DS2-VASc (congestive 
heart failure, hypertension, age ≥75  years, diabetes 
mellitus, stroke/transient ischemic attack, vascular dis-
ease, age 65–74 years, sex category) score for stroke 
risk stratification, including those from the Asia Pacific 
Heart Rhythm Society and other Asian countries.2–6
Although there are many similarities in the rec-
ommendations for antithrombotic therapy in these 
guidelines, the consensus is that antithrombotic 
therapy is not recommended for low-risk patients 
with AF (ie, CHA2DS2-VASc score of 0 [male] or 
1 [female]) without nonsex stroke risk factors. In 
many published studies, the CHA2DS2-VASc score 
is conventionally calculated for baseline risk fac-
tors, but the risk score would be increased during 
the follow-up period, between 1 and 10  years (or 
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more). Because AF patients get older and acquire 
more new comorbidities over time, they would no 
longer be low risk. In addition, age is probably the 
most important risk factor for ischemic stroke in AF 
among individual risk factors, particularly for “low-
risk” patients,7 and about 90% develop ≥1 new 
stroke risk factor before presentation with ischemic 
stroke.8
The objective of this study was to investigate a co-
hort of low-risk patients with AF in relation to their de-
velopment of incident comorbidities and their use of 
oral anticoagulation therapy.
METHODS
The data that support the findings of this study are 
available from the corresponding author on reason-
able request.
Overall, 14 441 nonvalvular patients with AF aged 
≥20  years out of a total of 363 188 patients from 
January 2013 to December 2017 were selected from 
the National Health Insurance Service (NHIS) data-
base as the study population. Prevalent nonvalvular 
AF was identified using the International Classification 
of Diseases, Tenth Revision, Clinical Modification (ICD-
10-CM) code (I48) and baseline absence of mitral ste-
nosis or mechanical heart valves (ICD-10-CM codes 
I05 or Z952–Z954). We excluded patients who had a 
history of thromboembolic events or intracranial hem-
orrhage and included only patients with newly diag-
nosed AF. Patients receiving oral anticoagulants (OAC; 
warfarin or non–vitamin K antagonist OAC), aspirin, 
or other antiplatelet agents at baseline were also ex-
cluded. To establish a low-risk patient population, male 
patients with a CHA2DS2-VASc score of ≥1 and female 
patients with a CHA2DS2-VASc score of ≥2 were ex-
cluded. A flowchart of study enrollment is shown in 
Figure 1.
In this study, patients were censored at discontin-
uation of the initial OAC or on switching to a different 
OAC. We defined discontinuation as having no addi-
tional refill for at least 60 days since the end of supply 
for a prescription. Approval for this study was obtained 
from the ethics review board of Dong-A University 
Hospital (number 15–130), and informed consent was 
waived.
Clinical End Points
The clinical end point was the occurrence of ischemic 
stroke (ICD-10-CM codes I63 or I64), intracranial hem-
orrhage (ICD-10-CM codes I60–62) or hospitalization 
for gastrointestinal bleeding (ICD-10 codes K22.6, 
K25.0, K25.2, K25.4, K25.6, K26.0, K26.2, K26.4, 
K26.6, K27.0, K27.2, K27.4, K27.6, K28.0, K28.2, 
K28.4, K28.6, K29.0, K62.5, K92.0, K92.1, K92.2) for 
major bleeding, and all-cause death during the follow-
up period. A composite clinical outcome (ischemic 
stroke, major bleeding, all-cause death) was also as-
sessed. Clinical outcomes were determined according 
to OAC use or non-OAC use during follow-up. Non-
OAC use could include no antithrombotic therapy or 
aspirin; the latter drug is not recommended for stroke 
prevention because it is ineffective and unsafe in pa-
tients with AF.2–6
Statistical Analysis
Continuous variables are expressed as mean values 
with standard deviations, and categorical variables 
CLINICAL PERSPECTIVE
What Is New?
• We studied a cohort of initially low-risk patients 
with AF (CHA2DS2-VASc score of 0 [male], 1 [fe-
male]) in relation to their development of inci-
dent comorbidities and their treatment on oral 
anticoagulation therapy.
• We show that approximately 30% of low-risk AF 
patients acquire new risk factors over 2 years.
• Patients should be reassessed regularly to ad-
equately identify those with incident stroke risk 
factors that would merit thromboprophylaxis 
for the prevention of stroke and the composite 
outcome (ischemic stroke, major bleeding, all-
cause death).
What Are the Clinical Implications?
• In this analysis of a large cohort of low-risk pa-
tients with AF who were not on oral anticoagulant 
therapy at baseline, patients with ≥1 new-onset 
risk factor who were subsequently treated with 
an oral anticoagulant at follow-up  had signifi-
cantly lower event rates of ischemic stroke and 
the composite clinical outcome compared with 
those not treated with oral anticoagulants.
Nonstandard Abbreviations and Acronyms
AF atrial fibrillation
HR hazard ratio
ICD-10-CM  International Classification of 
Diseases, Tenth Revision, Clinical 
Modification
IQR interquartile range
NHIS National Health Insurance Service
NOAC  non–vitamin K antagonist oral 
anticoagulant
OAC oral anticoagulant
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are presented as frequencies (percentages). For the 
clinical end points, we calculated incidence rates per 
100 person-years, and estimated CIs for the incidence 
rates assuming that the number of cases followed 
a Poisson distribution. The risk of events was as-
sessed using the Cox proportional hazards analysis. 
Figure 1. Flowchart of study enrollment.
AF indicates atrial fibrillation; NOAC, non-vitamin K antagonist oral anticoagulant; non-OAC, no antithrombotic therapy or 
aspirin (vitamin K antagonist oral anticoagulant); and OAC, oral anticoagulant.
Table 1. Characteristics of AF Patients With Baseline CHA2DS2-VASc Scores of 0 (Male) or 1 (Female)
Total CHA2DS2-VASc score 0 (male) CHA2DS2-VASc score 1 (female)
N=14 441
OAC Non-OAC OAC Non-OAC
n=2506 n=6490 n=1540 n=3905
Age, y 54.3±9.7 54.1±10.1 53.9±10.2 54.3±9.6 54.6±9.9
<55 6806 (47.1) 1052 (42.0) 3123 (48.1) 686 (44.6) 1945 (49.8)
55–64 7635 (52.9) 1454 (58.0) 3367 (51.9) 854 (55.4) 1960 (50.2)
Clinical history
Dyslipidemia 3103 (21.5) 461 (18.4) 1428 (22.0) 306 (19.8) 908 (23.3)
Chronic lung disease 1241 (8.6) 203 (8.1) 556 (8.6) 140 (9.1) 342 (8.7)
Medication
Aspirin 4893 (66.1) 3020 (66.2)
Warfarin 2451 (33.1) 1519 (33.3)
NOAC 55 (0.7) 21 (0.5)
Rivaroxaban 29 (0.4) 11 (0.2)
Dabigatran 13 (0.2) 5 (0.1)
Apixaban 8 (0.1) 3 (0.1)
Edoxaban 5 (0.1) 2 (0.04)
Follow-up, y, median (IQR) 2.1 (1.4–2.4) 2.0 (1.5–2.6) 2.2 (1.5–2.5) 2.0 (1.4–2.5) 2.1 (1.5–2.6)
Values are n (%) or mean±SD, except as noted. Non-OAC indicates no antithrombotic therapy or aspirin. AF indicates atrial fibrillation; IQR, interquartile range; 
NOAC, non–vitamin K antagonist oral anticoagulant; and OAC, oral anticoagulant (warfarin or non–vitamin K antagonist oral anticoagulant).
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Cumulative incidences of clinical end points were con-
structed as Kaplan–Meier estimates according to the 
therapy used and were compared using the log-rank 
test. All reported P values are 2-sided, and P<0.05 was 
considered statistically significant. Data manipulation 
and statistical analyses were conducted using SAS 
v9.3 (SAS Institute).
Results
Table 1 summarizes the characteristics of the 14 441 
patients with AF (CHA2DS2-VASc score of 0 [male] or 
1 [female]) who were included in the analysis: 8996 
(62.2%) were male. Among 14  441 patients with AF, 
4046 (28.0%; ie, 2506 male [27.9%] and 1540 female 
[28.3%]) received OACs during follow-up. The median 
follow-up duration was 2.1  years (interquartile range, 
1.4–2.4) in total patients.
Changes in CHA2DS2-VASc Score
Among a total of 14 441 initially low-risk patients with 
AF, increasing CHA2DS2-VASc scores ≥1 were found 
in 2615 (29.1%) male and 1650 (30.3%) female pa-
tients with AF during a median follow-up of 2.2 years 
(Table 2). Of the study cohort, 4265 patients with AF 
acquired ≥1 new comorbidity with an annual risk of 
13.9% per year for increasing CHA2DS2-VASc score 
(risk/year: 6.72% for hypertension, 5.64% for age 
≥65 years, 2.53% for congestive heart failure, 1.97% 
for diabetes mellitus, 1.17% for vascular diseases) 
(Table 3). The cumulative incidence rate for increas-
ing CHA2DS2-VASc scores ≥1 are shown in Figure 2.
OAC Use Compared With Non-OAC Use
Rates of ischemic stroke, major bleeding, all-cause 
death, and composite outcomes (ischemic stroke, 
major bleeding, all-cause death) in relation to OAC 
and non-OAC use among patients with AF and base-
line low risk (CHA2DS2-VASc score of 0 [male] or 1 
[female]) are shown in Figure 3. During median follow-
up of 2.1  years, the annual ischemic stroke rates for 
non-OAC and OAC use by male groups with baseline 
CHA2DS2-VASc score of 0 were 0.72% and 0.49%, re-
spectively. During follow-up, the annual incidence of is-
chemic stroke was 0.85% and 0.72% for non-OAC and 
OAC use by female groups with a baseline CHA2DS2-
VASc score of 1, respectively.
In patients with ≥1 new-onset risk factor, the inci-
dence rates of ischemic stroke in men were 1.43% and 
0.92% per year for the non-OAC and OAC groups, 
respectively. In female patients, the incidence rates 
of ischemic stroke were 1.51% and 1.11% per year 
for non-OAC and OAC users, respectively. Male and 
female patients using OACs (hazard ratio, 0.62 [95% 
CI, 0.44–0.82; P=0.003] and 0.65 [95% CI, 0.47–0.84; 
P=0.007], respectively) had significantly lower risk of 
ischemic stroke than non-OAC users. However, rates 
of major bleeding (intracranial hemorrhage or hospital-
ization for gastrointestinal bleeding) increased in OAC 
users compared with non-OAC users (per year, male: 
2.03% versus 1.57%; female: 1.96% versus 1.52%). 
Consequently, OAC use was associated with higher 
risk of major bleeding than non-OAC use (male: HR, 
1.48 [95% CI, 1.29–1.67; P=0.008]; female: HR, 1.47 
[95% CI, 1.28–1.66; P=0.009]). The incidence rates of 
all-cause death in male patients were 1.71% and 1.29% 
per year for non-OAC and OAC users, respectively. 
The rates of all-cause death in non-OAC- and OAC-
treated female patients were 1.54% and 1.30% per 
year, respectively. OAC use was associated with lower 
risk of all-cause death compared with non-OAC use in 
male patients (HR, 0.67; 95% CI, 0.49–0.88; P=0.009) 
but not female patients (HR, 0.82; 95% CI, 0.63–1.02; 
P=0.185).
In both male and female patients with ≥1 new-on-
set risk factor, there was a reduction in the annual risk 
of the composite outcome (ischemic stroke, major 
bleeding, and all-cause death) with OAC use (4.18% 
and 4.21% per year, respectively) compared with 
non-OAC use (4.55% and 4.49% per year, respec-
tively). OAC use was associated with better compos-
ite outcome in both male patients (HR, 0.78; 95% CI, 
0.61–0.95; P=0.042) and female patients (HR, 0.79; 
Table 3. Annual risks of ≥1 new-onset comorbidity
New-onset comorbidity
Annual IR (95% CI)
Total (n=4265) Male (n=2615) Female (n=1650)
Age ≥65 y 5.64 (5.07–6.21) 5.51 (4.94–6.08) 5.71 (5.15–6.27)
Hypertension 6.72 (6.11–7.33) 6.63 (6.02–7.24) 6.81 (6.19–7.43)
Diabetes mellitus 1.97 (1.51–2.43) 1.89 (1.43–2.35) 2.01 (1.57–2.46)
CHF 2.53 (1.84–3.22) 2.49 (1.80–3.18) 2.71 (2.02–3.40)
Vascular disease 1.17 (0.71–1.63) 1.27 (0.81–1.73) 1.42 (0.96–1.89)
Any 13.89 (13.36–14.42) 12.93 (12.40–13.46) 14.52 (13.98–15.06)
Follow-up, y, median (IQR) 2.16 (1.47–2.89) 2.13 (1.44–2.85) 2.21 (1.50–2.93)
CHF indicates congestive heart failure; IR, incidence rate (events divided by 100 person-years, percentage per year); and IQR, interquartile range.
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95% CI, 0.62–0.96; P=0.045) with ≥1 new-onset 
risk factor compared with non-OAC users (Figure 4). 
The cumulative incidence of the clinical outcomes is 
shown in Figures 5 and 6.
DISCUSSION
In this analysis of a large cohort of low-risk patients 
with AF(CHA2DS2-VASc score of 0 [male] or 1 [female]) 
Figure 2. Cumulative incidence rate for increasing CHA2DS2-VASc score ≥1.
 
Figure 3. Event rates for OAC use compared with non-OAC use in patients with atrial fibrillation with a baseline 
CHA2DS2-VASc score of 0 (male) or 1 (female).
IR, incidence rate (events divided by 100 person-years, percentage per year); and OAC, oral anticoagulant.
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who were not on OAC therapy at baseline, patients 
with ≥1 new-onset risk factor subsequently treated with 
OACs at follow-up had significantly lower event rates 
of ischemic stroke and composite clinical outcomes 
(ischemic stroke, major bleeding, all-cause death) 
compared with non-OAC users. This study provides 
the first report of a significant benefit with antithrom-
botic therapy in patients with AF who have ≥1 incident 
Figure 4. Event rates for OAC use compared with non-OAC use in patients with atrial fibrillation and ≥1 new-onset 
risk factor. Male (A) or female (B).
IR, incidence rate (events divided by 100 person-years, percentage per year); and OAC, oral anticoagulant.
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nonsex CHA2DS2-VASc risk factor. Of note, approxi-
mately 13.9% of patients with AF per year would have 
an increasing CHA2DS2-VASc score ≥1 with new co-
morbidities acquired during follow-up, the most com-
mon being hypertension.
International guidelines suggest that antithrom-
botic therapy is not recommended for low-risk pa-
tients with AF (ie. CHA2DS2-VASc score of 0 [male] 
or 1 [female]) without nonsex stroke risk factors.2–6 
The 2006 American College of Cardiology and 
American Heart Association AF guidelines and the 
2018 CHEST (American College of Chest Physicians) 
guidelines state that individual risk varies over time, 
so the need for anticoagulation must be reevaluated 
periodically in all patients with AF.9 This step is partic-
ularly important for low-risk patients with AF at base-
line because these patients usually do not receive 
OAC therapy when AF is diagnosed. However, new 
Figure 5. Cumulative incidence of clinical outcomes according to OAC therapy in patients with atrial fibrillation and a 
baseline CHA2DS2-VASc score of 0 (male) or 1 (female).
OAC indicates oral anticoagulant.
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comorbidities could develop thereafter that could 
substantially increase the risk of ischemic stroke.
Indeed, stroke risk of patients with AF is not static. 
The CHA2DS2-VASc score could increase as patients 
get older and accumulate more comorbidities.8 In ad-
dition, the 2018 CHEST guidelines and the 2019 fo-
cused update of the American College of Cardiology, 
the American Heart Association, and the Heart 
Rhythm Society AF guidelines both recommend the 
reassessment of stroke risk and the need for anti-
coagulant therapy at periodic intervals.5,10 Data from 
the current study show that CHA2DS2-VASc score 
should be regularly reassessed for optimizing stroke 
prevention with antithrombotic therapy.11,12 The cur-
rent age threshold for OAC treatment (age <65 years) 
that defines “low risk” has even been proposed to 
be lowered to age <50 or <55  years among Asian 
patients.13,14
In this study, the annual ischemic stroke rates for non-
OAC-treated male patients (CHA2DS2-VASc score of 0) 
and female patients (CHA2DS2-VASc score of 1) were 
0.72% and 0.85% per year, respectively; these rates are 
well below the treatment threshold for OAC.1 However, 
among non-OAC users with increasing CHA2DS2-VASc 
scores ≥1, the annual risk of ischemic stroke was in-
creased to 1.43% per year for men and 1.51% per year for 
women, which is above the stroke rate threshold where 
OAC use is beneficial.1 In addition, OAC use significantly 
decreased the risk of ischemic stroke and composite 
clinical outcome compared with non-OAC use.
Study Limitations
First, this study is based on a nationwide cohort study 
using Korean NHIS data and may be limited by errors 
of coding, missing data, and laboratory measure-
ments. Furthermore, because AF diagnoses and the 
estimation of clinical outcomes were based on diag-
nostic codes registered by the physicians, the diagno-
sis of AF and events could be inaccurate. Second, the 
registry data also fail to provide any details regarding 
drug changes over time and some unmeasurable con-
founding factors such as physician decision. For this 
reason, in the main analysis, we sought to adjust for 
several lists of potential confounders by including the 
confounders in the Cox model; this makes the problem 
of confounding by indication less of an issue, although 
it cannot be ruled out completely. Third, our study has 
selection bias (prevalence incidence bias) and informa-
tion bias (follow-up bias).15 The relatively short period 
of the occurrence of new risk factors among patients 
initially having a CHA2DS2-VASc score of 0 (male) or 
1 (female) could have resulted from an incomplete di-
agnostic assessment at baseline. Fourth, we were not 
able to clearly confirm the cause of ischemic stroke, 
which in some cases could have been due to AF-related 
Figure 6. Cumulative incidence of clinical outcomes according to OAC therapy in patients with atrial fibrillation and ≥1 or 0 
new-onset risk factor: male (A) or female (B).
OAC indicates oral anticoagulant.
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thromboembolism or atherosclerosis and thrombosis 
of the cerebral artery. Fifth, inaccurate diagnosis of co-
morbidities can lead to misclassification of CHA2DS2-
VASc score for intermediate-risk patients with AF. 
Finally, the OAC group included patients treated with 
warfarin or non–vitamin K antagonist OACs. The num-
ber of non–vitamin K antagonist OAC users was low in 
this study for the follow-up duration because low-risk 
patients with AF were included. The non-OAC group 
would include patients on no antithrombotic therapy or 
aspirin; the latter is ineffective for stroke prevention in 
AF and is not safe.16 In addition, some aspirin use may 
be “over the counter.”
CONCLUSIONS
Low-risk patients with AF should be regularly reas-
sessed to adequately identify patients with incident 
stroke risk factors that would merit thromboprophy-
laxis for the prevention of stroke and the composite 
outcome.
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